Organogenesis Holdings (ORGO) Other Non-Current Assets (2017 - 2026)
Organogenesis Holdings' (ORGO) quarterly Other Non-Current Assets came in at $16.1 million in Q1 2026, up 176.47% year-on-year from $5.8 million in Q1 2025, and up 75.26% quarter-over-quarter from $9.2 million in Q4 2025.
Organogenesis Holdings (ORGO) Other Non-Current Assets (2017 - 2026) Analysis & Trends
Organogenesis Holdings' Other Non-Current Assets history runs 10 years deep, the most recent figure standing at $16.1 million for Q1 2026.
- On a quarterly basis, Other Non-Current Assets rose 176.47% year-over-year to $16.1 million in Q1 2026; TTM through Mar 2026 was $16.1 million, a 176.47% increase from a year earlier, with the FY2025 full-year figure at $9.2 million, up 83.88% from the prior year.
- Other Non-Current Assets advanced to $16.1 million in Q1 2026 per ORGO's latest filing, from $9.2 million in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $16.1 million in Q1 2026 and bottomed at $1.3 million in Q3 2023.
- The 5-year median for Other Non-Current Assets is $5.0 million (2024), against an average of $5.5 million.
- Across the five-year window, Other Non-Current Assets fell 16.87% in 2023 and surged 358.58% in 2024, its largest moves.
- Year by year, Other Non-Current Assets stood at $1.5 million in 2022, then soared by 294.08% to $6.0 million in 2023, then declined by 16.44% to $5.0 million in 2024, then soared by 83.88% to $9.2 million in 2025, then jumped by 75.26% to $16.1 million in 2026.
- Per Business Quant, the three latest ORGO Other Non-Current Assets figures stand at $16.1 million (Q1 2026), $9.2 million (Q4 2025), and $14.4 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 49.22 Mn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 1.79 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 351.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 491.06 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 233.20 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 1.11 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 73.60 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 295.00 Mn |
| 10 | Organogenesis Holdings | 310.55 Mn | 218.45 Mn | 11.46 Mn | 16.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 16.13 Mn |
| Dec 31, 2025 | 9.20 Mn |
| Sep 30, 2025 | 14.41 Mn |
| Jun 30, 2025 | 8.73 Mn |
| Mar 31, 2025 | 5.83 Mn |
| Dec 31, 2024 | 5.01 Mn |
| Sep 30, 2024 | 5.01 Mn |
| Jun 30, 2024 | 5.85 Mn |
| Mar 31, 2024 | 6.71 Mn |
| Dec 31, 2023 | 5.99 Mn |
| Sep 30, 2023 | 1.32 Mn |
| Jun 30, 2023 | 1.39 Mn |
| Mar 31, 2023 | 1.46 Mn |
| Dec 31, 2022 | 1.52 Mn |
| Sep 30, 2022 | 1.59 Mn |
| Jun 30, 2022 | 1.67 Mn |
| Mar 31, 2022 | 1.47 Mn |
| Dec 31, 2021 | 1.54 Mn |
| Sep 30, 2021 | 1.61 Mn |
| Jun 30, 2021 | 605,000.00 |